Literature DB >> 20423472

Burden of disease and costs of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom.

Oliver Rivero-Arias1, Alastair Gray, Jane Wolstenholme.   

Abstract

BACKGROUND: To estimate life years and quality-adjusted life years (QALYs) lost and the economic burden of aneurysmal subarachnoid haemorrhage (aSAH) in the United Kingdom including healthcare and non-healthcare costs from a societal perspective.
METHODS: All UK residents in 2005 with aSAH (International Classification of Diseases 10th revision (ICD-10) code I60). Sex and age-specific abridged life tables were generated for a general population and aSAH cohorts. QALYs in each cohort were calculated adjusting the life tables with health-related quality of life (HRQL) data. Healthcare costs included hospital expenditure, cerebrovascular rehabilitation, primary care and community health and social services. Non-healthcare costs included informal care and productivity losses arising from morbidity and premature death.
RESULTS: A total of 80,356 life years and 74,807 quality-adjusted life years were estimated to be lost due to aSAH in the UK in 2005. aSAH costs the National Health Service (NHS) pound168.2 million annually with hospital inpatient admissions accounting for 59%, community health and social services for 18%, aSAH-related operations for 15% and cerebrovascular rehabilitation for 6% of the total NHS estimated costs. The average per patient cost for the NHS was estimated to be pound23,294. The total economic burden (including informal care and using the human capital method to estimate production losses) of a SAH in the United Kingdom was estimated to be pound510 million annually.
CONCLUSION: The economic and disease burden of aSAH in the United Kingdom is reported in this study. Decision-makers can use these results to complement other information when informing prevention policies in this field and to relate health care expenditures to disease categories.

Entities:  

Year:  2010        PMID: 20423472      PMCID: PMC2874525          DOI: 10.1186/1478-7547-8-6

Source DB:  PubMed          Journal:  Cost Eff Resour Alloc        ISSN: 1478-7547


  17 in total

Review 1.  Economic note: cost of illness studies.

Authors:  S Byford; D J Torgerson; J Raftery
Journal:  BMJ       Date:  2000-05-13

Review 2.  Aneurysmal subarachnoid hemorrhage.

Authors:  Jose I Suarez; Robert W Tarr; Warren R Selman
Journal:  N Engl J Med       Date:  2006-01-26       Impact factor: 91.245

Review 3.  Cost-of-illness studies : a review of current methods.

Authors:  Ebere Akobundu; Jing Ju; Lisa Blatt; C Daniel Mullins
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 4.  Subarachnoid haemorrhage.

Authors:  Jan van Gijn; Richard S Kerr; Gabriel J E Rinkel
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

Review 5.  Cost-of-illness studies in the United States: a systematic review of methodologies used for direct cost.

Authors:  Gerd Clabaugh; Marcia M Ward
Journal:  Value Health       Date:  2008 Jan-Feb       Impact factor: 5.725

6.  Cost of cardiovascular diseases in the United Kingdom.

Authors:  R Luengo-Fernández; J Leal; A Gray; S Petersen; M Rayner
Journal:  Heart       Date:  2006-05-15       Impact factor: 5.994

7.  Economic burden of cardiovascular diseases in the enlarged European Union.

Authors:  José Leal; Ramón Luengo-Fernández; Alastair Gray; Sophie Petersen; Mike Rayner
Journal:  Eur Heart J       Date:  2006-02-22       Impact factor: 29.983

8.  Description of quality of life and its predictors in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Majed J Katati; Sandra Santiago-Ramajo; Miguel Pérez-García; Miguel Meersmans-Sánchez Jofré; Raquel Vilar-Lopez; Maria Angeles Coín-Mejias; Alfonso Caracuel-Romero; Ventura Arjona-Moron
Journal:  Cerebrovasc Dis       Date:  2007-05-22       Impact factor: 2.762

9.  Population-based study of event-rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study).

Authors:  P M Rothwell; A J Coull; L E Silver; J F Fairhead; M F Giles; C E Lovelock; J N E Redgrave; L M Bull; S J V Welch; F C Cuthbertson; L E Binney; S A Gutnikov; P Anslow; A P Banning; D Mant; Z Mehta
Journal:  Lancet       Date:  2005-11-19       Impact factor: 79.321

10.  International subarachnoid aneurysm trial (ISAT) of neurosurgical clipping versus endovascular coiling in 2143 patients with ruptured intracranial aneurysms: a randomised comparison of effects on survival, dependency, seizures, rebleeding, subgroups, and aneurysm occlusion.

Authors:  Andrew J Molyneux; Richard S C Kerr; Ly-Mee Yu; Mike Clarke; Mary Sneade; Julia A Yarnold; Peter Sandercock
Journal:  Lancet       Date:  2005 Sep 3-9       Impact factor: 79.321

View more
  38 in total

1.  Effects of Radiation Exposure on the Cost-Effectiveness of CT Angiography and Perfusion Imaging in Aneurysmal Subarachnoid Hemorrhage.

Authors:  J Ivanidze; R A Charalel; I Shuryak; D Brenner; A Pandya; O N Kallas; K Kesavabhotla; A Z Segal; M S Simon; P C Sanelli
Journal:  AJNR Am J Neuroradiol       Date:  2017-01-12       Impact factor: 3.825

2.  Extending statistical learning for aneurysm rupture assessment to Finnish and Japanese populations using morphology, hemodynamics, and patient characteristics.

Authors:  Felicitas J Detmer; Sara Hadad; Bong Jae Chung; Fernando Mut; Martin Slawski; Norman Juchler; Vartan Kurtcuoglu; Sven Hirsch; Philippe Bijlenga; Yuya Uchiyama; Soichiro Fujimura; Makoto Yamamoto; Yuichi Murayama; Hiroyuki Takao; Timo Koivisto; Juhana Frösen; Juan R Cebral
Journal:  Neurosurg Focus       Date:  2019-07-01       Impact factor: 4.047

3.  Development and internal validation of an aneurysm rupture probability model based on patient characteristics and aneurysm location, morphology, and hemodynamics.

Authors:  Felicitas J Detmer; Bong Jae Chung; Fernando Mut; Martin Slawski; Farid Hamzei-Sichani; Christopher Putman; Carlos Jiménez; Juan R Cebral
Journal:  Int J Comput Assist Radiol Surg       Date:  2018-08-09       Impact factor: 2.924

4.  Comparison of statistical learning approaches for cerebral aneurysm rupture assessment.

Authors:  Felicitas J Detmer; Daniel Lückehe; Fernando Mut; Martin Slawski; Sven Hirsch; Philippe Bijlenga; Gabriele von Voigt; Juan R Cebral
Journal:  Int J Comput Assist Radiol Surg       Date:  2019-09-04       Impact factor: 2.924

5.  From GWAS to the clinic: risk factors for intracranial aneurysms.

Authors:  Ynte M Ruigrok; Gabriel Je Rinkel
Journal:  Genome Med       Date:  2010-09-10       Impact factor: 11.117

6.  Associations of hemodynamics, morphology, and patient characteristics with aneurysm rupture stratified by aneurysm location.

Authors:  Felicitas J Detmer; Bong Jae Chung; Carlos Jimenez; Farid Hamzei-Sichani; David Kallmes; Christopher Putman; Juan R Cebral
Journal:  Neuroradiology       Date:  2018-11-19       Impact factor: 2.804

Review 7.  Anesthetic management of patients with intracranial aneurysms.

Authors:  Alaa A Abd-Elsayed; Anthony S Wehby; Ehab Farag
Journal:  Ochsner J       Date:  2014

8.  Controlled Hypercapnia Enhances Cerebral Blood Flow and Brain Tissue Oxygenation After Aneurysmal Subarachnoid Hemorrhage: Results of a Phase 1 Study.

Authors:  Thomas Westermaier; Christian Stetter; Ekkehard Kunze; Nadine Willner; Judith Holzmeier; Judith Weiland; Stefan Koehler; Christopher Lotz; Christian Kilgenstein; Ralf-Ingo Ernestus; Norbert Roewer; Ralf Michael Muellenbach
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

Review 9.  Spreading Depolarizations: A Therapeutic Target Against Delayed Cerebral Ischemia After Subarachnoid Hemorrhage.

Authors:  David Y Chung; Fumiaki Oka; Cenk Ayata
Journal:  J Clin Neurophysiol       Date:  2016-06       Impact factor: 2.177

10.  External validation of cerebral aneurysm rupture probability model with data from two patient cohorts.

Authors:  Felicitas J Detmer; Daniel Fajardo-Jiménez; Fernando Mut; Norman Juchler; Sven Hirsch; Vitor Mendes Pereira; Philippe Bijlenga; Juan R Cebral
Journal:  Acta Neurochir (Wien)       Date:  2018-10-30       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.